In 1913 Finzi advocated irradiation of uninvolved sites in patients with Hodgkin's disease in an attempt to procure long term RFS (Finzi, 1913) . The work of Gilbert (1939) , Peters (1950) , and Kaplan (1962) , led to the general acceptance of megavoltage extended field radiotherapy for patients with localised Hodgkin's disease because of the greatly improved RFS. Relapses occur following radiotherapy alone, and relapse rates of 20-30% have been associated with mantle radiotherapy in stage IA-IIB patients (Carmel & Kaplan, 1976; Peckham et al., 1975; Timothy et al., 1978) . Kaplan defined adverse prognostic factors for his patients and then advocated radiotherapy ranging from involved field treatment for favourable histology (pathologically staged IA disease in favourable sites), to total nodal irradiation for PS IB/IIB disease . However, even when extended field therapy with lung irradiation to patients with a high risk of relapse was given the overall supradiaphragmatic relapse rate was 20% in PS I and II disease (Carmel & Kaplan, 1976) .
Combination chemotherapy developed by DeVita et al. (1970) improved the cure rate of patients with advanced stage HD. MOPP or MVPP , are standard treatments for stage IIIB/IV disease. When chemotherapy is used to salvage relapsed patients whose localised disease was treated by radiotherapy alone only about half are found to have long term survival (Portlock et al., 1978) . For these reasons we initiated a randomised trial in 1974 to assess the role of adjuvant MVPP in improving RFS and overall survival in PS IA-IIB disease. It was also hoped that adverse prognostic factors at presentation would allow identification of patients who might benefit from adjuvant chemotherapy (ACT).
The trial protocol was written in 1974 when there were few adjuvant trials in progress. Now several reports of adjuvant therapy are available for PS IA-IIB Hodgkin's disease. (Coltman et al., 1979; Wiernik et al., 1979; Hoppe et al., 1982; Nissen & Nordentoft, 1982 (Lukes et al., 1966) . Staging was according to the Ann Arbor classification (Carbone et al., 1971) .
Bulk disease was defined as a mass of lymph nodes outside the chest measuring .5cm in any one axis. Mediastinal bulk was present if the ratio of the maximum width of mediastinal disease to the maximum chest diameter was one third or more. Patients were examined at first review after radiotherapy for remission status. A complete remission was defined as absence of all clinical, biochemical and radiological evidence of disease. Patients were then randomised to ACT or follow up alone.
Treatment
The radiotherapy was given by the "mantle" technique. Anterior and posterior opposed 4 Mv fields were used to encompass the major node areas in the upper half of the body. The fields extended from the external auditory meatus superiorly to the eleventh thoracic vertebra inferiorly, covering the axillae laterally. The dose delivered at the midplane was 3500 cGy in 20 fractions, in 4 weeks. From the onset of treatment the majority of lung tissue was shielded by individually fashioned blocks. The spinal cord was shielded for half the posterior treatments, and a compensatory anterior mediastinal lung field was used to deliver 600cGy on the final treatment day. There was consequently a dose gradient from 2900 cGy in the posterior mediastinum to 3900 cGy in the anterior mediastinum.
The adjuvant chemotherapy given was 6 courses of MVPP at 6-weekly intervals, mustine 6mgm-2 (max. 10mg) IV days 1 & 8, vinblastine 6mgm-2 (max 10mg) IV days 1 & 8, prednisolone 40mg day-1 orally days 1-14, and procarbazine 100mgm-2 orally days 1-14.
Patient review
Patients have been reviewed regularly in the clinic. (After treatment had finished they were reviewed monthly for the first year, 2-monthly in the second, 3-monthly in the third, four monthly in the fourth, 6-monthly in the fifth, and yearly thereafter). The median duration of follow up was 62 months (range 16-97 months).
Statistical methods
The effects of several variables on survival and RFS have been analysed by calculating KaplanMeier curves, which were then compared using the logrank test (Peto et al., 1977 ). Cox's proportional hazards model (Cox, 1972) had been used to determine the most significant variables tnat affect RFS. Both overall survival and RFS have been calculated from the completion of radiotherapy.
Results
Fifty-five patients were in the radiotherapy (RT) alone group, and 59 in the ACT group. Patient characteristics were similar in the two groups (Table I ). All patients attained a complete Twenty-five of the patients randomised to ACT received less than 6 courses of MVPP. Seven received no chemotherapy at all -two patients refused chemotherapy after randomisation, 3 patients were not given MVPP on medical grounds (one had severe post RT lethargy and weight loss, one had hepatitis on liver biopsy, and one had an isolated C7 nerve palsy investigated until it was too late to give MVPP), and two had no MVPP for technical reasons (difficulties with venepuncture). These 7 patients have been included in the ACT group for statistical analysis in order to avoid any bias in the treatment comparisons.
Of the other 18 patients, 8 discontinued chemotherapy after developing myelosuppression (two developed septicaemia), 5 after developing mild infections, two refused further chemotherapy due to toxicity, 3 were stopped due to toxicity (one had severe gastrointestinal colic, one had steroid induced depression and suicidal tendency, and one had severe lethargy).
Relapse free survival (RFS)
The overall 5 year RFS was 81%; 69% in the RT group and 93% in the ACT group (P=0.002). (Figure 1 ). Twenty patients have relapsed, 16/55 in the RT group (29%) and 4/59 in the ACT group (7%). In the latter group two who had a CR with radiotherapy alone, relapsed through ACT and died, and one did not receive adjuvant treatment following the finding of hepatitis at laparotomy liver biopsy (discussed later). disease was present relapse involving the primary site occurred in 6/12 cases, whereas none of the relapses occurring in patients without bulky disease occurred in the site of initial disease. Mediastinal bulk was present in 8/55 patients treated by RT alone, and 10/59 treated with ACT. Relapse occurred in seven of these 18 patients (39%), 5/8 RT (62%), and 2/10 ACT (20%).
An analysis of the site of relapse in relation to radiotherapy field showed nine relapses outside the field, six within, and five relapses occurred simultaneously inside and outside the radiotherapy field. Ten relapses occurred in nodes alone, and 6 in extranodal sites alone (one in bone, 2 in liver and bone, one in the lung, liver, diaphragm, and pericardium, one in the pleura and chest wall, and one in the humerus and overlying skin). Four patients had simultaneous nodal and extranodal relapse (3 mediastinum and lung, and one in paraaortic glands and bone). Of the 4 patients relapsing in the ACT group, 2 relapsed during ACT and died of HD (both had PS IIB disease with mediastinal bulk at presentation). One patient with pulmonary and hilar relapse failed to respond to MVPP or radiotherapy and died of disease. The fourth patient received no ACT (hepatitis on liver biopsy), and achieved a CR on MVPP.
Sixteen relapsed after RT alone, and 13 achieved a CR on chemotherapy (11 MVPP and 2 Chlorambucil VPP). Seven of these patients received adjuvant radiotherapy to sites of relapse. One patient received no treatment because the relapse was diagnosed at post mortem. Another patient failed to achieve a CR after relapse in the skin and bone and died of HD, septicaemia and disseminated herpes zoster. The remaining patient achieved a CR using MVPP after mediastinal and pleural relapse. He then had a second relapse and died of disseminated herpes zoster and HD. Of the remaining 6 patients dying with active disease, 3 were in each treatment group. Two receiving ACT relapsed through chemotherapy. The other relapsed with mediastinal and lung disease and died of pneumonia and progressing HD. Of the three dying after radiotherapy alone, in one patient HD was identified in the paratracheal glands at postmortem examination following death from E.coli septicaemia. There had been no clinical evidence of relapse. Of the other two, one died in his first, and the other in his second relapse.
Discussion
This trial of adjuvant chemotherapy following radiotherapy for localised Hodgkin's disease was different from other randomised trials in two respects -the radiotherapy was the same in both arms of the trial (mantle RT), and MVPP was used rather than MOPP. It has been shown that remission rates and survival in advanced Hodgkin's disease are similar for MOPP and MVPP therapy, however MVPP has less neurotoxicity (Nicholson et al., 1970; Sutcliffe et al., 1978; Crowther, 1979; DeVita et al., 1980) . We have shown that 5 year RFS for PS IA-IIB HD patients has been significantly improved by adjuvant MVPP, although there was no improvement in overall survival. Four other randomised studies of adjuvant chemotherapy in patients with localised pathologically staged HD have been published. They are summarised in Table   VI . Stanford compared radiotherapy alone using varied fields (involved field, mantle, +lung or subdiaphragmatic irradiation depending on the patient prognostic factors), with involved or extended field radiotherapy followed by 6 courses of MOPP Rosenberg et al., 1979; Hoppe et al., 1982) . In their study, ACT significantly improved RFS in PS IA/IIA disease but not in IB/IIB disease. This contrasts with our study which showed benefit for patients with B symptoms following ACT. The probable reason for this difference may be the more extensive radiotherapy fields given at Stanford to patients with B symptoms in the RT alone arm. Stanford showed borderline survival advantage at 10 years follow-up after ACT to patients with IA/IIA disease but the overall survival of Stanford patients with mediastinal bulk at presentation was the same in both arms of the trial.
The Southwest Oncology Group (SWOG) has also shown an improved RFS after ACT. The compared involved field RT plus adjuvant MOPP with extended field RT alone, and they found mediastinal disease, E disease and B symptoms to be adverse prognostic factors associated with increased RFS when given ACT. They also failed to show an overall survival advantage from ACT (Coltman et al., 1979) .
A study from Denmark compared TNI with mantle RT followed by six courses of MOPP. This again showed RFS benefit from ACT but no overall survival advantage (Nissen & Nordentoft, 1982 (Nissen et al., 1980; Timothy et al., 1979; Wiernik et al., 1979) . Less favourable rates have been reported following RT alone in PS IA-IIB patients (Portlock et al., 1978) . Salvage results depend upon the site of relapse and extent of disease.
The number of courses of ACT is controversial, and studies in clinically staged patients with three courses of MOPP following radiotherapy show improved RFS (Andrieu et al., 1980; Teillet et al., 1981) .
Against the efficacy of chemotherapy one must weigh the toxicity, especially the development of sterility and second malignancies (Nissen et al., 1980; Wiernik et al, 1979; Andrieu et al., 1980; Crowther, 1980) . The combination of adriamycin, bleomycin, vinblastine and DTIC (ABVD) seems to be as effective as MOPP, but causes less sterility and second malignancies (Santoro et al., 1983) . However, in combination with radiotherapy ABVD may be associated with an increased risk of pulmonary fibrosis. Adjuvant chemotherapy may cause myelotoxicity. Severe neutropenia (neutrophils < 1.0 x 1091-1) occurred in three of our patients. Two developed septicaemia. These three and five others with asymptomatic thrombocytopenia discontinued the adjuvant chemotherapy.
Since overall survival is not improved most patients with localised HD can be safely and effectively treated with radiotherapy alone. Adverse prognostic factors should be taken into account so that therapy can be chosen for each patient ensuring maximum chance of cure with minimal short and long term treatment associated complications. This approach has recently been critically reviewed (Crowther, 1984) . Our results and those of other groups show a high relapse rate in patients with B symptoms (Aisenberg, 1978; Mintz et al., 1979; Coltman et al., 1979) , and bulky mediastinal disease (Lee et al., 1980; Mauch et al., 1978) treated by RT alone. Combined modality treatment of mediastinal bulk with large volumes of lung and heart irradiation may be associated with morbidity due to pericarditis and pneumonitis. The role of prophylactic lung irradiation for patients with mediastinal bulk needs further assessment to determine efficacy and long term complications (Lee et al., 1981; Torti et al., 1981 
